PLx Pharma Receives NCI Grant for Research of Novel Aspirin Formulation to Prevent Colorectal Cancer
“This NCI grant will enable us to further advance research of our novel formulation of aspirin for the prevention of colorectal cancer, the fourth most commonly diagnosed cancer in the U.S. today,” stated
The role of aspirin in platelet pharmacology is well-established, and aspirin itself remains the foundational drug used for cardiovascular disease prevention.
Further development of PLx’s novel phosphatidylcholine (PC)-associated aspirin (Aspirin-PC) for the prevention of colorectal cancer and potentially other cancers is supported by two recently published studies in peer-reviewed journals of the
The NCI grant, Award Number R42CA171408, will be disbursed in two installments:
1 Lichtenberger LM et al. Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1. Cancer
2 Huang Y et al. Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. Mol Cancer Ther; 15(12)
About PLx Pharma Inc.
PLxGuard works by targeting delivery of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this delivery system has the potential to improve the absorption of many drugs currently on the market or in development, such as aspirin, and may provide high-risk cardiovascular and stroke patients with more reliable and predictable antiplatelet efficacy as compared to enteric coated aspirin. PLx also believes PLxGuard has the potential to reduce acute GI side effects—including erosions, ulcers and bleeding—associated with aspirin and ibuprofen, and potentially other drugs.
To learn more about
NCI leads the National Cancer Program and the NIH’s efforts to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website at cancer.gov or call NCI's Cancer Information Service at 1-800-4-CANCER.
NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the
Forward Looking Statements
Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for commercializing or selling any products or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to PLx may identify forward-looking statements. PLx cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by PLx to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of PLx’s proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property and risks that PLx may lack the financial resources and access to capital to fund proposed operations. Further information on the factors and risks that could affect PLx’s business, financial conditions and results of operations are contained in PLx’s filings with the U.S. Securities and Exchange Commission (
Contact Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793 E: email@example.com Media: Ann Smith, Coyne Public Relations T: 973-588-2385 E: firstname.lastname@example.org